STOCK TITAN

Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. will participate in a fireside chat and investor meetings at the Cantor Global Healthcare Conference in New York City on September 26-28, 2023.
Positive
  • Investors can gain insights from the fireside chat and 1x1 meetings with Crinetics Pharmaceuticals' management.
Negative
  • No negative takes found.

SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-28, 2023.

Details of the fireside chat are as follows:

Date: Tuesday, September 26, 2023
Time: 1:00 p.m. Eastern Time

The live and archived webcast will be accessible on the Events & Presentations page in the Investors section on the Crinetics’ website at www.crinetics.com/events.

If you are interested in arranging a 1×1 meeting with management, please contact your Cantor representative.

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894 a first-in-class, investigational, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of Cushing’s disease and congenital adrenal hyperplasia. All of the Company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, hyperinsulinism, diabetes and obesity.

Contacts:
Chas Schultz
VP, IR & Corporate Communications
cschultz@crinetics.com
(858) 450-6464

Investors:
Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com
(212) 915-2577

Media:
Jenn Gordon
Spectrum Science
jgordon@spectrumscience.com
(202) 957-7795


FAQ

When and where is the Cantor Global Healthcare Conference being held?

The Cantor Global Healthcare Conference is being held in New York City on September 26-28, 2023.

How can I access the webcast of the fireside chat?

The live and archived webcast will be accessible on the Events & Presentations page in the Investors section on Crinetics' website at www.crinetics.com/events.

How can I arrange a 1x1 meeting with Crinetics Pharmaceuticals' management?

To arrange a 1x1 meeting with management, please contact your Cantor representative.

Crinetics Pharmaceuticals, Inc.

NASDAQ:CRNX

CRNX Rankings

CRNX Latest News

CRNX Stock Data

3.72B
64.74M
1.92%
97.19%
6.3%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SAN DIEGO

About CRNX

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.